Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$2.03
-$0.06(-4.88%)
At close: 4:00 PM EST
$2.03
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.21 - $13.00
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$5.47M
Enterprise Value-$21.67
Total Cash (Recent Filing)$21.53M
Total Debt (Recent Filing)$680.03K
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.05
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageExtremely low debt relative to equity provides structural financial flexibility for a development-stage biotech. It reduces near-term solvency risk and preserves optionality to fund R&D or restructure capital without heavy interest burdens, supporting pipeline execution over months.
Multi-year Cash RunwayA stated cash runway into 2029 materially reduces the probability of urgent financing within the 2–6 month horizon, allowing management to pursue planned data readouts and registrational planning. This lowers short-term dilution risk and supports sustained clinical progress.
ProTide Platform & Diversified Clinical PipelineOwning a differentiated ProTide technology and multiple clinical-stage candidates spreads binary risk and supports durable upside if trial data are positive. Platform-led discovery plus multiple assets increases the chance of a development success or attractive partnerships over time.
Bears Say
No Product Revenue; Large Net LossesThe absence of product revenue and sustained multi‑million dollar net losses mean the company must rely on external funding to sustain operations. Continued losses erode equity and increase execution risk if capital access tightens, a persistent constraint for clinical-stage biotechs.
Negative Cash GenerationPersistently negative operating and free cash flow, despite some improvement, indicate ongoing burn to fund trials. This structural cash outflow pattern elevates dependency on financing and can force program reprioritization or dilution if spending accelerates or unforeseen costs arise.
Dependence On Equity Authorizations/fundingActive requests for share capital restructuring and fresh allotment authorities signal reliance on equity financing. Over the medium term this raises dilution risk and execution risk if shareholder support falters, making long‑term program funding contingent on capital market access.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.21 and its highest was $13.00 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $5.47M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Aug 13, 2026 which is in 24 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on May 14, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.36% Other Institutional Investors
99.64% Public Companies and
Individual Investors